Androgen deprivation therapy is the initial treatment for men with advanced prostate cancer.
Almost all these patients eventually develop progressive castration‐resistant prostate cancer …

Clinical endpoints for drug development in prostate cancer : Current Opinion in Urology
Clinical endpoints for drug development in prostate cancer : Current Opinion in Urology Log in …

Prostate cancer is one of the most common causes of death in males. Even if treatment is
often of curative intent in early stages of the disease, up to 50% of patients relapse after …

Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

Until recently, few therapeutic options were available for patients with castration-resistant
prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit …

CONTEXT: Castration-resistant prostate cancer (CRPC) refers to patients who no longer
respond to surgical or medical castration. Standard treatment options are limited …

Opinion statement Prostate cancer is the most common non-cutaneous cancer diagnosed in
men and the second leading cause of male cancer deaths in the USA. While most cases are …

Treatment options for men with metastatic prostate cancer have greatly expanded in the last
decade. Androgen receptor pathway inhibitors, taxane cytotoxic therapy, poly (ADP-ribose) …

Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …

Seven years passed since docetaxel/prednisone demonstrated and overall survival benefit,
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …